ACL Share Price Performance
AU$2.79
-0.93 (-25.00%)
17.9% undervalued intrinsic discount
AU$3.40
Fair Value
Price AU$2.79
AnalystConsensusTarget AU$3.40
AnalystHighTarget AU$5.00
AnalystLowTarget AU$3.15
Fair ValueAU$3.40
Share Pricen/a
Australian Clinical Labs Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 35 Fair Values set on narratives written by author
ACL Community Narratives
AN
Fair Value AU$3.4 17.9% undervalued intrinsic discount
ACL: Share Buyback And Acquisition Plans Will Drive Strong Shareholder Returns
0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
Fair Value AU$4.73 41.1% undervalued intrinsic discount
Novel Genetic Tests And Digital Tools Will Capture Aging Demand
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value AU$2.9 3.8% undervalued intrinsic discount
Rising Costs And Competition Will Squeeze Margins Yet Preserve Value
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ACL: Share Buyback And Acquisition Plans Will Drive Strong Shareholder Returns
Key Takeaways Automation, AI, and digital billing initiatives are set to lower costs, expand margins, and improve cash collection and profit. Launches in advanced genetic and oncology testing and ongoing operational consolidation will drive sustainable high-margin growth and greater efficiency.Read more
0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
AU$3.4
17.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
4.42% p.a.
Profit Margin
5.45%
Future PE
16.24x
Price in 2028
AU$4.12
Novel Genetic Tests And Digital Tools Will Capture Aging Demand
Key Takeaways Expansion of high-margin genetic tests and innovative automation positions the company for outsized revenue and earnings growth ahead of market expectations. Monetizing previously unfunded test volumes and disciplined portfolio management will drive strong cash generation and safeguard long-term profitability.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$4.73
41.1% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
5.42% p.a.
Profit Margin
5.71%
Future PE
20.88x
Price in 2028
AU$5.71
Rising Costs And Competition Will Squeeze Margins Yet Preserve Value
Key Takeaways Revenue growth and margins face pressure from government cost controls, rebate cuts, and increased competition, despite stable demand from an aging population and chronic diseases. Expansion into specialized testing and digital health may offer opportunities, but rising labor costs, workforce shortages, and technology-driven commoditization threaten sustainable profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AU$2.9
3.8% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
4% p.a.
Profit Margin
4.99%
Future PE
15.24x
Price in 2028
AU$3.5
Trending Discussion
Recently Updated Narratives
AN
ACL: Share Buyback Program Will Drive Shareholder Value Over The Next Year
Fair Value: AU$3.4 17.9% undervalued intrinsic discount
23 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Costs And Competition Will Squeeze Margins Yet Preserve Value
Fair Value: AU$2.9 3.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Novel Genetic Tests And Digital Tools Will Capture Aging Demand
Fair Value: AU$4.73 41.1% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Australian Clinical Labs Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 25, 2026
- 0.17
- 36.54%
- 4.37%
- 24.4%
About ACL
- Founded
- 2020
- Employees
- 4700
- CEO
- WebsiteView website
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
